U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C30H42N2O9
Molecular Weight 574.6625
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of KW-2478 FREE BASE

SMILES

CCC1=C(O)C=C(O)C(C(=O)C2=CC(OC)=C(OCCN3CCOCC3)C=C2)=C1CC(=O)N(CCOC)CCOC

InChI

InChIKey=VFUXSYAXEKYYMB-UHFFFAOYSA-N
InChI=1S/C30H42N2O9/c1-5-22-23(19-28(35)32(11-13-37-2)12-14-38-3)29(25(34)20-24(22)33)30(36)21-6-7-26(27(18-21)39-4)41-17-10-31-8-15-40-16-9-31/h6-7,18,20,33-34H,5,8-17,19H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C30H42N2O9
Molecular Weight 574.6625
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

KW-2478 is a novel and potent non-ansamycin inhibitor of heat shock protein 90 designed to overcome the limitations, including low water solubility and hepatotoxicity, of 17-allylamino-17-demethoxygeldanamycin (17-AAG). KW-2478 exerts a strong antitumor activity against multiple myeloma (MM) cells with various chromosomal translocations. KW-2478 inhibits cell growth and apoptosis associated with Hsp90 client protein degradation. Recent study results have revealed that KW-2478 is able to deplete Hsp90 client Cdk9 and the phosphorylated 4E-BP1, a transcriptional kinase and a transcription inhibitor respectively, leading to reduced expression of FGFR3, c-Maf, and cyclin D1. KW-2478 suppresses tumor growth and induces the degradation of client proteins in tumors in NCI-H929 s.c. inoculated model at doses of 100 mg/kg or more. KW-2478 reduces both serum M protein and MM tumor burden in the bone marrow in OPM-2/GFP i.v. inoculated mouse model at doses of 100 mg/kg.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
3.8 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
6838 ng/mL
176 mg/m² single, intravenous
KW-2478 plasma
Homo sapiens
1990 ng/mL
47 mg/m² single, intravenous
KW-2478 plasma
Homo sapiens
2620 ng/mL
71 mg/m² single, intravenous
KW-2478 plasma
Homo sapiens
5410 ng/mL
132 mg/m² single, intravenous
KW-2478 plasma
Homo sapiens
645 ng/mL
14 mg/m² 1 times / day single, intravenous
KW-2478 plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
11501 ng × h/mL
176 mg/m² single, intravenous
KW-2478 plasma
Homo sapiens
2758 ng × h/mL
47 mg/m² single, intravenous
KW-2478 plasma
Homo sapiens
3197 ng × h/mL
71 mg/m² single, intravenous
KW-2478 plasma
Homo sapiens
7876 ng × h/mL
132 mg/m² single, intravenous
KW-2478 plasma
Homo sapiens
992 ng × h/mL
14 mg/m² 1 times / day single, intravenous
KW-2478 plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
5.43 h
176 mg/m² single, intravenous
KW-2478 plasma
Homo sapiens
6.6 h
47 mg/m² single, intravenous
KW-2478 plasma
Homo sapiens
6.29 h
71 mg/m² single, intravenous
KW-2478 plasma
Homo sapiens
5.71 h
132 mg/m² single, intravenous
KW-2478 plasma
Homo sapiens
6.05 h
14 mg/m² 1 times / day single, intravenous
KW-2478 plasma
Homo sapiens

PubMed

Sample Use Guides

In Vivo Use Guide
KW-2478 130 mg/m^2 Administered Days 1, 4, 8 and 11 of a 21 day cycle
Route of Administration: Intravenous
In Vitro Use Guide
OPM-2/GFP and KMS-11 cells were used for activity evaluation. The cells were plated into 96-well plates and treated with KW-2478. After 72 hours of cultivation, cell viability was determined using Cell Proliferation Reagent WST-1 (Roche Diagnostics). WST reagent was added to the wells, followed by incubation for 4 hours at 37°C. After that, the absorbance at 450 nm with reference at 650 nm was measured with a microplate spectrophotometer.
Substance Class Chemical
Record UNII
QY50S617NM
Record Status Validated (UNII)
Record Version